Generation, characterization, and medical utilization of laser-produced emission continua

Intense continua of electromagnetic radiation of very brief duration are formed in the interaction of focused ultra-short terawatt laser pulses with matter. Two different kinds of experiments, which have been performed utilizing the Lund 10 Hz titanium-doped sapphire terawatt laser system are being described, where visible radiation and X-rays, respectively, have been generated. Focusing into water leads to the generation of a light continuum through self-phase modulation. The propagation of the light through tissue was studied addressing questions related to optical mammography and specific chromophore absorption. When terawatt laser pulses are focused onto a solid target with high nuclear charge Z, intense X-ray radiation of few ps duration and with energies exceeding hundreds of keV is emitted. Biomedical applications of this radiation are described, including differential absorption and gated-viewing imaging

Evaluation of the activity of CYP2C19 in Gujrati and Marwadi subjects living in Mumbai (Bombay)

BACKGROUND: Inherited differences in the metabolism and disposition of drugs, and genetic polymorphisms in the targets of drug therapy (e.g., receptors), can greatly influence efficacy and toxicity of medications. Marked interethnic differences in CYP2C19 (a member of the cytochrome P-450 enzyme superfamily catalyzing phase I drug metabolism) which affects the metabolism of a number of clinically important drugs have been documented. The present study evaluated the activity of CYP2C19 in normal, healthy Gujrati and Marwadi subjects by phenotyping (a western Indian population). METHODS: All subjects received 20 mg of omeprazole, which was followed by blood collection at 3 hrs to estimate the metabolic ratio of omeprazole to 5-hydroxyomeprazole. The analysis was done by HPLC. RESULTS: It was seen that 10.36% of this population were poor metabolizers(PM) whereas 89.63% were extensive metabolizers(EM). CONCLUSION: A genotyping evaluation would better help in identifying population specific genotypes and thus help individualize drug therapy

Towards the clinical implementation of pharmacogenetics in bipolar disorder.

BackgroundBipolar disorder (BD) is a psychiatric illness defined by pathological alterations between the mood states of mania and depression, causing disability, imposing healthcare costs and elevating the risk of suicide. Although effective treatments for BD exist, variability in outcomes leads to a large number of treatment failures, typically followed by a trial and error process of medication switches that can take years. Pharmacogenetic testing (PGT), by tailoring drug choice to an individual, may personalize and expedite treatment so as to identify more rapidly medications well suited to individual BD patients.DiscussionA number of associations have been made in BD between medication response phenotypes and specific genetic markers. However, to date clinical adoption of PGT has been limited, often citing questions that must be answered before it can be widely utilized. These include: What are the requirements of supporting evidence? How large is a clinically relevant effect? What degree of specificity and sensitivity are required? Does a given marker influence decision making and have clinical utility? In many cases, the answers to these questions remain unknown, and ultimately, the question of whether PGT is valid and useful must be determined empirically. Towards this aim, we have reviewed the literature and selected drug-genotype associations with the strongest evidence for utility in BD.SummaryBased upon these findings, we propose a preliminary panel for use in PGT, and a method by which the results of a PGT panel can be integrated for clinical interpretation. Finally, we argue that based on the sufficiency of accumulated evidence, PGT implementation studies are now warranted. We propose and discuss the design for a randomized clinical trial to test the use of PGT in the treatment of BD

Elemental biological imaging by differential absorption with a laser-produced x-ray source

We demonstrate the novel application of hard x rays emitted by a laser-produced plasma for differential imaging of elements. An x-ray-emitting laser-produced plasma, obtained by the focusing of radiation from a 10-Hz terawatt laser, is used for biological imaging. The x-ray source can be arranged to yield characteristic x-ray emission lines with photon energies that bridge the K absorption edge of a chosen atomic species. One can obtain element-specific radiographs by recording transillumination images for different target materials on digital image plates and by subsequently subtracting or dividing the images. Successful phantom and experimental animal imaging are performed utilizing tantalum and gadolinium as target materials for the terawatt laser and gadolinium as the imaged contrast agent